

The *rel* Gene Is Essential for In Vitro Growth of *Staphylococcus aureus*

DANIEL GENTRY,* TONG LI,† MARTIN ROSENBERG, AND DAMIEN McDEVITT

SmithKline Beecham Pharmaceuticals, Collegeville, Pennsylvania 19426

Received 22 February 2000/Accepted 6 June 2000

The stringent response in *Staphylococcus aureus* is mediated by the nucleotide guanosine pentaphosphate, whose synthesis is catalyzed by the product of the *rel* gene. We report here that the *rel* gene is essential for the in vitro growth of *S. aureus*, distinguishing it from all other bacteria tested for this requirement.

The stringent response is a pleiotropic physiological reaction exhibited by bacteria in response to amino acid deprivation or to inhibition of tRNA amino acylation. The hallmark of the stringent response is an abrupt cessation of stable RNA synthesis, but it also involves the stimulation of some genes involved in various anabolic functions and of some stationary-phase-specific genes (3). Limitation for other nutrients elicits a similar response, so that the stringent response has come to be referred to as a response to all nutrient limitations. The stringent response is usually mediated by the nucleotides guanosine 3',5'-bis(diphosphate) (ppGpp) and guanosine 3'-diphosphate,5'-triphosphate (pppGpp). In *Staphylococcus aureus*, only pppGpp accumulates (4). The two nucleotides appear to be functionally interchangeable and are collectively known as (p)ppGpp.

Most work on the stringent response has been performed with *Escherichia coli*, which possesses two (p)ppGpp synthetases encoded by the *relA* and *spoT* genes (7, 17). The RelA enzyme is required for the rapid increase in (p)ppGpp synthesis following amino acid starvation (or inhibition of amino acylation of tRNA). The homologous SpoT enzyme is required for maintenance of basal levels of (p)ppGpp and is responsible for (p)ppGpp accumulation following nutrient limitations that do not involve amino acid starvation. SpoT is a bifunctional enzyme that also catalyzes the degradation of (p)ppGpp (1, 12). *E. coli* strains with *relA* and *spoT* deleted lack detectable (p)ppGpp and exhibit a pleiotropic phenotype (7, 17) that includes attenuation in pathogenic isolates (D. R. Gentry, A. P. Bryant, I. Critchley, and A. Marra, submitted for publication).

Genomic sequencing results reveal a trend in which gram-negative organisms possess two synthetases similar to what is seen in *E. coli* while most gram-positive organisms appear to have a single gene, generally called *rel*, which encodes a bifunctional enzyme responsible for both (p)ppGpp synthesis and degradation (2, 9, 10, 14). Studies have shown that a *Bacillus subtilis rel* deletion mutant lacks detectable (p)ppGpp and has difficulty in responding to stress (15). Also, a *Streptococcus pneumoniae rel* mutant exhibits attenuation in a murine respiratory tract infection model and a gerbil otitis media model (R. Greenwood, A. P. Bryant, A. Marra, K. A. Ingraham, D. Holmes, and D. R. Gentry, submitted for publication). These observations predict that similar *rel* deletions in gram-

positive human pathogens may result in decreased virulence and poor stress responsiveness. This paper reports our attempts to isolate a *rel* deletion mutant of the important human pathogen *S. aureus*. In contrast to other gram-positive organisms studied to date, in *S. aureus rel* was found to be essential for bacterial viability.

The *S. aureus rel* gene was identified from sequence data generated during an effort to sequence the *S. aureus* genome. As with most gram-positive bacteria, upstream of *rel* is the *apt* gene, encoding adenine phosphoribosyltransferase, while downstream is a highly conserved gene of unknown function called *orf1*. The *rel* gene product is identical to the predicted Rel sequence from the previously published *S. aureus rel* gene (5). The Rel enzyme is bifunctional, as indicated by the ability of a plasmid carrying the *rel* gene to complement the growth defects of *E. coli* mutants defective in (p)ppGpp synthesis or degradation (Greenwood et al., submitted). A plasmid-borne *rel* insertion-deletion construct was isolated in the following manner. A 2.6-kb *SalI-EcoRI* fragment containing the *rel* locus was inserted into the *SalI-EcoRI* sites of pBluescript. The internal *Mlu-NdeI* fragment (1 kb) in the *rel* gene was replaced by the *S. aureus tetK* gene from plasmid pCW59 (16). Thus, the final construct contained upstream sequence-*tetK*-resistance marker-downstream sequence (3.9 kb) cloned into pBluescript (shown schematically in Fig. 1). So that a counterscreen could be used to detect double-recombination allelic replacement events following transformation, the 3.9-kb *SalI-EcoRI rel* deletion-insertion fragment was cloned into pBluescriptErm, generating the plasmid pEKerm. Plasmid pBluescriptErm is pBluescript with an erythromycin resistance cassette inserted into the *NaeI* site.

Plasmid pEKerm was transformed into *S. aureus* RN4220. A total of five transformants were obtained from tryptic soy agar (TSA; Difco) plates containing 5 µg of tetracycline per ml. Both PCR and Southern hybridization analysis confirmed that all five of the transformants were cointegrants. Because cointegrants contain the insertion-deletion mutation with sufficient flanking sequences to recombine at the *rel* locus, the deletion mutation should be obtainable via generalized phage transduction if the *rel* gene is nonessential. An attempt to resolve a cointegrant by φ11 transduction yielded 2,200 Tc^r transductants, none of which were Em^s, suggesting that it was impossible to resolve the cointegrant and that *rel* was probably essential for in vitro growth. For nonessential genes, the frequency of cointegrant resolution is typically between 0.5 and 5%. We then sought to determine if we could resolve the cointegrant into a strain with the wild-type gene provided in *trans* on a plasmid. The *rel* gene, on a 5.3-kb *EcoRI* fragment, was cloned into the Cm^r plasmid pSK265 to generate plasmid

* Corresponding author. Mailing address: SmithKline Beecham Pharmaceuticals, 1250 S. Collegeville Rd., Collegeville, PA 19426. Phone: (610) 917-7504. Fax: (610) 917-7901. E-mail: dan_r_gentry@sbphrd.com.

† Present address: PharmaNet Inc., Blue Bell, PA 19422.




FIG. 1. Schematic representation of the *rel* region on the *S. aureus* chromosome. (Top) Wild-type (wt) orientation of the *apt*, *rel*, and *orf1* genes. The numbers indicate the first and last codons of the *rel* gene. (Middle) Orientation of the *rel* gene in the deletion construct. The numbers indicate the codons on the flanks of the *tetK* insertion; thus, codons 143 through 414 of *rel* are deleted in the construct. (Bottom) Orientation of the *orf1* deletion. This drawing is not to scale.

pSK*rel*. In addition to *rel*, pSK*rel* contains part of the downstream gene, *orf1*, as well as about 2.0 kb of sequence upstream of *rel*. This plasmid was introduced into *S. aureus* 8325-4. In this strain it was possible to resolve the cointegrant (26 of 2,000 transductants [1.3%] were $\text{Em}^r \text{Cm}^r$) within the expected frequency range. For 2 of the 26 resolved mutants, the pSK*rel* plasmid had integrated illegitimately into the chromosome (Cm^r). For these two mutants, the natural *rel* locus was clearly disrupted, as predicted. All the remaining 24 resolved mutants possessed extrachromosomal plasmid pSK*rel*. PCR (10 of 10 mutants) and sequencing analysis (2 of 2 mutants) confirmed the correct structure of those resolved mutants.

A phage lysate was prepared from one of the resolved mutants and used to transduce the Tc^r marker. Transductants were isolated; however, 100% of these (70 of 70) had also inherited the pSK*rel* Cm^r plasmid. Transfer of plasmids via transduction is commonly observed in *S. aureus*. Thus, it was not possible to dissociate the *rel* deletion mutation and the *rel* complementing plasmid. This result further indicated that *rel* is essential for in vitro growth.

As mentioned above, plasmid pSK*rel* carries a fragment of *orf1*. To ensure that the lethality of the *rel* deletion is not due to polar effects on the expression of this gene, a deletion strain was constructed in which the entire gene was replaced with an erythromycin resistance cassette. Results show that *orf1* is not essential, as indicated by the ability to readily isolate allelic replacement mutants. This mutant exhibits no obvious phenotype and has not been studied any further.

S. aureus stands out among the gram-positive organisms by its dependence on *rel* for growth. This puts *S. aureus* on the extreme end of the variability of the effect of mutations on (p)ppGpp metabolism. The reason for this is open to speculation. While Rel-related enzymes are the most broadly distributed (p)ppGpp synthetases, other, unrelated enzymes that can catalyze (p)ppGpp synthesis are known. For example, *Streptovorticillium morookaensis* and some of its relatives produce an extracellular nucleotide 3'-pyrophosphokinase (11). Additionally, polynucleotide phosphorylase from *Streptomyces antibioticus* catalyzes the synthesis of (p)ppGpp in vitro (8). If another source of (p)ppGpp synthesis were present in *S. aureus* and if *rel* is the sole source of (p)ppGpp degradation, the *rel* gene would be essential because its absence would lead to prohibitively high intracellular levels of (p)ppGpp. A homolog of the *Streptovorticillium morookaensis* nucleotide 3'-pyrophosphokinase is not present in the several *S. aureus* genomic se-

quence databases available, and only *Streptomyces antibioticus* polynucleotide phosphorylase has been shown to synthesize (p)ppGpp in vitro [and its role in vivo (p)ppGpp synthesis is unclear]. It therefore seems that if another (p)ppGpp synthetic enzyme exists in *S. aureus*, it is not related to any enzyme known to have the activity. It is formally possible that the N-terminal 142 amino acids of the *S. aureus* Rel protein, which is still intact in the deletion construct made, has (p)ppGpp synthetic activity but no degradative activity. Given the lack of residual activity of similar peptides of *E. coli* SpoT (6), this seems very unlikely.

Based on what is known of the *E. coli* system (7, 17), a likely cause of the lethality of the *rel* deletion is some defect in amino acid biosynthesis. Such a defect is not likely to be due to a straightforward amino acid auxotrophy, given that the medium, TSA, used in the experiments described here is likely to contain a full complement of amino acids provided for by the predominant ingredients, tryptone and soytone. This is best shown by the ability of an *E. coli* $\Delta\text{relA } \Delta\text{spoT}$ strain to grow well in this medium (data not shown). Also, TSA, in our experience, is one of the better media for propagating *S. aureus* in terms of both growth rate and growth yield. A more complicated amino acid defect, such as amino acid sensitivities, is more likely. An example of an amino acid sensitivity is the inability of *E. coli* *relA* mutants to grow in the presence of serine, methionine, and glycine because isoleucine biosynthesis is inhibited under such conditions (13).

TSA could be deficient for some other nutrient whose biosynthesis is under tight (p)ppGpp control. In addition to tryptone and soytone, TSA contains glucose, NaCl, and K_2HPO_4 . It is therefore possible that it is deficient in a key vitamin or nucleobase, given the lack of added vitamins or yeast extract. A defect in the ability to use the carbon sources in TSA is less likely, given the carbohydrates provided by soytone and the added glucose. Finally, a defect in the transport of any nutrient cannot be excluded. It is also possible that *rel* has a function other than its role in (p)ppGpp metabolism and that it is this function that is essential in *S. aureus*.

Further work is clearly needed in this area, with a key requirement for a conditional *rel* mutant. We have constructed a strain in which the *rel* gene is under control of a regulatable promoter, and our initial finding, i.e., that the strain is not viable in the absence of *rel* expression, supports our conclusions reported here. Unfortunately, the strain has proven to be unstable, and further refinement is needed before it can be effectively used to address this problem.

The work was funded in part by DARPA grant N65236-97-1-5810.

REFERENCES

- An, G., J. Justesen, R. J. Watson, and J. D. Friesen. 1979. Cloning the *spoT* gene of *Escherichia coli*: identification of the *spoT* gene product. *J. Bacteriol.* **137**:1100-1110.
- Avarbock, D., J. Salem, L. Li, Z. Wang, and H. Rubin. 1999. Cloning and characterization of a bifunctional RelA/SpoT homologue from *Mycobacterium tuberculosis*. *Gene* **233**:261-269.
- Cashel, M., D. R. Gentry, V. J. Hernandez, and D. Vinella. 1996. The stringent response, p. 1458-1496. In F. C. Neidhardt, R. Curtiss III, J. L. Ingraham, E. C. C. Lin, K. B. Low, B. Magasanik, W. Reznikoff, M. Riley, M. Shaechter, and A. E. Umberger (ed.), *Escherichia coli* and *Salmonella*: cellular and molecular biology, 2nd ed. ASM Press, Washington, D.C.
- Cassels, R., B. Oliva, and D. Knowles. 1995. Occurrence of the regulatory nucleotides ppGpp and pppGpp following induction of the stringent response in staphylococci. *J. Bacteriol.* **177**:5161-5165.
- Fujimura, T., and K. Murakami. 1997. Increase of methicillin resistance in *Staphylococcus aureus* caused by deletion of a gene whose product is homologous to lytic enzymes. *J. Bacteriol.* **179**:6294-6301.
- Gentry, D. R., and M. Cashel. 1996. Mutational analysis of the *Escherichia coli* *spoT* gene identifies distinct but overlapping regions involved in ppGpp synthesis and degradation. *Mol. Microbiol.* **19**:1373-1384.

7. **Hernandez, V. J., and H. Bremer.** 1991. *Escherichia coli* ppGpp synthetase II activity requires *spoT*. J. Biol. Chem. **266**:5991–5999.
8. **Jones, G. H., and M. J. Bibb.** 1996. Guanosine pentaphosphate synthetase from *Streptomyces antibioticus* is also a polynucleotide phosphorylase. J. Bacteriol. **178**:4281–4288.
9. **Martinez-Costa O. H., M. A. Fernandez-Moreno, and F. Malpartida.** 1998. The *relA/spoT*-homologous gene in *Streptomyces coelicolor* encodes both ribosome-dependent (p)ppGpp-synthesizing and -degrading activities. J. Bacteriol. **180**:4123–4132.
10. **Mechold, U., M. Cashel, D. Gentry, and H. Malke.** 1996. Functional analysis of a *relA/spoT* gene homolog from *Streptococcus equisimilis*. J. Bacteriol. **178**:1401–1411.
11. **Muta, S., K. Osoegawa, S. Ezaki, M. Zubair, S. Kuhara, J. Mukai, and R. Dixon.** 1992. *Streptomyces* ATP nucleotide 3'-pyrophosphokinase and its gene. Nucleic Acids Symp. Ser. **422**:165–166.
12. **Sy, J.** 1977. In vitro degradation of guanosine 5'-diphosphate, 3'-diphosphate. Proc. Natl. Acad. Sci. USA **74**:5529–5533.
13. **Uzan, M., and A. Danchin.** 1976. A rapid test for the *relA* mutation in *E. coli*. Biochem. Biophys. Res. Commun. **69**:751–758.
14. **Wehmeier L., A. Schafer, A. Burkovski, R. Kramer, U. Mechold, H. Malke, A. Puhler, and J. Kalinowski.** 1998. The role of the *Corynebacterium glutamicum rel* gene in (p)ppGpp metabolism. Microbiology **144**:1853–1862.
15. **Wendrich, T. M., and M. A. Marahiel.** 1997. Cloning and characterization of a *relA/spoT* homologue from *Bacillus subtilis*. Mol. Microbiol. **26**:65–67.
16. **Wilson, C. R., S. E. Skinner, and W. V. Shaw.** 1981. Analysis of two chloramphenicol resistance plasmids from *S. aureus*: insertional inactivation of Cm resistance, mapping of restriction sites, and construction of cloning vectors. Plasmid **5**:245–258.
17. **Xiao, H., M. Kalman, K. Ikehara, S. Zemel, G. Glaser, and M. Cashel.** 1991. Residual guanosine 3',5'-bispyrophosphate synthetic activity of *relA* null mutants can be eliminated by *spoT* null mutations. J. Biol. Chem. **266**:5980–5990.